Johannes Gerardus Chri Schikan Sells 800 Shares of Pharvaris (NASDAQ:PHVS) Stock

Pharvaris N.V. (NASDAQ:PHVS) Director Johannes Gerardus Chri Schikan sold 800 shares of the stock in a transaction dated Tuesday, September 22nd. The stock was sold at an average price of $36.19, for a total transaction of $28,952.00. Following the transaction, the director directly owned 115,167 shares of the company’s stock, valued at $4,167,893.73. This represents a 0.69% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Johannes Gerardus Chri Schikan also recently made the following trade(s):

• On Thursday, September 17th, Johannes Gerardus Chri Schikan sold 200,000 shares of Pharvaris stock. The shares were sold at an average price of $35.00, for a total value of $7,000,000.00.
• On Tuesday, June 30th, Johannes Gerardus Chri Schikan sold 30,712 shares of Pharvaris stock. The stock was sold at an average price of $35.49, for a total value of $1,089,968.88.
• On Monday, June 29th, Johannes Gerardus Chri Schikan sold 6,888 shares of Pharvaris stock. The shares were sold at an average price of $35.05, for a total value of $241,424.40.

Pharvaris Trading Down 1.6%

NASDAQ:PHVS traded down $0.52 during mid-day trading on Thursday, hitting $32.55. The company had a trading volume of 201,154 shares, compared to its average volume of 413,337. Pharvaris N.V. has a 1 year low of $20.65 and a 1 year high of $43.25. The business has a fifty day simple moving average of $35.36 and a 200-day simple moving average of $31.93. The firm has a market capitalization of $2.13 billion, a price-to-earnings ratio of -10.67 and a beta of -2.33.

Pharvaris (NASDAQ:PHVS) last announced its earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.06). As a group, research analysts anticipate that Pharvaris N.V. will post -3.12 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have weighed in on PHVS. Royal Bank Of Canada lifted their target price on Pharvaris from $52.00 to $62.00 and gave the company an “outperform” rating in a research note on Wednesday, September 9th. HSBC raised Pharvaris to an “overweight” rating in a research report on Thursday, August 13th. Rosenblatt Securities set a $60.00 price target on shares of Pharvaris in a research report on Wednesday, September 9th. UBS Group set a $79.00 price objective on shares of Pharvaris in a research report on Wednesday, September 9th. Finally, Wells Fargo & Company lifted their price objective on Pharvaris from $55.00 to $65.00 and gave the company an “overweight” rating in a research report on Wednesday, September 9th. Thirteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $59.87.

Institutional Trading of Pharvaris

A number of large investors have recently bought and sold shares of the stock. venBio Partners LLC acquired a new stake in shares of Pharvaris during the second quarter worth approximately $160,569,809. 5AM Venture Management LLC bought a new stake in Pharvaris during the 2nd quarter worth approximately $27,581,008. BlackRock Inc. acquired a new stake in Pharvaris during the 2nd quarter valued at $26,677,000. Elmind Capital LP acquired a new stake in Pharvaris during the 2nd quarter valued at $18,180,435. Finally, Seven Fleet Capital Management LP boosted its stake in Pharvaris by 144.6% in the second quarter. Seven Fleet Capital Management LP now owns 774,501 shares of the company’s stock worth $26,782,000 after purchasing an additional 457,804 shares in the last quarter.

Pharvaris Company Profile

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.